Jacobs Levy Equity Management
HOWL icon

Jacobs Levy Equity Management’s Werewolf Therapeutics HOWL Stock Holding History

Jacobs Levy Equity Management’s Portfolio HOWL Stock Details HOWL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-101,221
Closed -$208K – 1008
2022
Q4 		$208K Buy
+101,221
New +$265K ﹤0.01% 903

Other funds holding HOWL

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
DF
DC Funds Mclean, Virginia $1.49M AUM 18.57% 1-Year Est. Return

Jacobs Levy Equity Management's HOWL Position: Q1 2023 in Review

Jacobs Levy Equity Management sold out of Werewolf Therapeutics (HOWL) in Q1 2023, closing a stake of 101,221 shares — an estimated $208K sold.

Jacobs Levy Equity Management first reported a position in HOWL in Q4 2022 and held it in 1 quarter. The position peaked at $208K in Q4 2022. 37 funds tracked by Wall St. Rank hold HOWL as of Q1 2023.

  • Jacobs Levy Equity Management reported no remaining Werewolf Therapeutics position as of Q1 2023 after selling out during the quarter.
  • Jacobs Levy Equity Management sold 101,221 Werewolf Therapeutics shares in Q1 2023, an estimated $208K.
  • Jacobs Levy Equity Management first reported a position in Werewolf Therapeutics in Q4 2022 and held it in 1 quarter.
  • Jacobs Levy Equity Management's Werewolf Therapeutics position peaked at $208K in Q4 2022.
  • 37 funds tracked by Wall St. Rank held Werewolf Therapeutics as of Q1 2023.

Based on Jacobs Levy Equity Management's 13F filing for Q1 2023, filed 15 May 2023.